Rob Puopolo, a partner in Goodwin’s Life Sciences practice, focuses his practice on representing public and privately held life sciences companies, as well as the venture capital firms, hedge funds and investment banks that focus on these companies.





Mr. Puopolo advises life sciences companies as general outside counsel on a variety of transactions. In addition to day-to-day representation and strategic advice to his clients, he regularly handles IPOs and public offerings, mergers and acquisitions, joint ventures and other strategic collaborations.

A selection of Mr. Puopolo’s recent representations include:

  • HOOKIPA Pharma in its $37.4 million (€33.2 million) Series D financing
  • ProKidney and its lead investor, Pablo Legorreta, founder and CEO of Royalty Pharma, in the acquisition of inRegen and Twin City Bio LLC for $62 million
  • CRISPR Therapeutics in its $56 million initial public offering, $200 million and $130 million public follow-on offerings
  • CRISPR Therapeutics in its, collaboration with ViaCyte, focused on stem cell therapies for the treatment of diabetes
  • Broadfin Capital on its investment in BioDelivery Sciences International’s $50 million public equity financing
  • Surface Oncology in its $119.5 million initial public offering
  • Goldman Sachs as lead underwriter in Arvinas’ $120 million initial public offering 
  • Pablo Legorreta, founder and CEO of Royalty Pharma, as lead investor in ITBMed’s $67 million equity financing round
  • Ra Pharmaceuticals in its $58 million public follow-on offering
  • Ginkgo Bioworks in its joint venture with Bayer focused on plant microbiome, with an initial investment of $100 million
  • Ginkgo Bioworks in its $14 million partnership with Glycosyn to optimize and scale the production of human milk oligosaccharides (hMOS)
  • Lysosomal Therapeutics, Inc. (LTI) in its exclusive option arrangement with Allergan plc
  • Versant Ventures in launching BlueRock Therapeutics, a next-generation regenerative medicine company, where Bayer and Versant are committing $225 million
  • Padlock Therapeutics in its sale to Bristol-Myers Squibb, with $225 million in upfront and near-term payments
  • F-star Alpha in connection with its exclusive option agreement with Bristol-Myers Squibb
  • CRISPR Therapeutics in its collaboration with Bayer, valued up to $335 million up front, and $38 million Series B financing
  • Alkermes in the sale of its manufacturing facility and the manufacturing and royalty revenue associated with products manufactured at the facility and global rights to Recro Pharma, Inc., for $170 million
  • Guerbet in a $270 million acquisition of Mallinckrodt's Contrast Media and Delivery Systems business
Professional Experience

Prior to rejoining Goodwin in 2014, Mr. Puopolo was a shareholder at Greenberg Traurig in Boston, where he served as co-chair of its emerging technology group. He has been licensed (inactive) in Massachusetts as a certified public accountant.


Mr. Puopolo has been repeatedly recognized as a Massachusetts Super Lawyer “Rising Star” by Law & Politics and Boston magazines. In law school, he was a member of the Suffolk University Transnational Law Review.

In The News









J.D., 1998
Suffolk University School of Law
(cum laude)
B.A., 1993
Northeastern University



Get In Touch
German Translation
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.


Search Other Lawyers
Recherche par Pratique